The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series

Hao Zeng1,2, Dongfang Wang3, Jingmin Nie4, Haoyu Liang5, Jiang Gu6, Anne Zhao1, Lixin Xu6, Chunhui Lang6, Xiaoping Cui6, Xinglan Guo7, Changlong Zhou8, Haibo Li1, Bin Guo7, Jinyong Zhang1, Qiang Wang7, Li Fang7, Wen Liu7, Yishan Huang7, Wei Mao3, Yaokai Chen8 and Quanming Zou1

Convalescent plasma (CP) transfusion has been indicated as a promising therapy in the treatment for other emerging viral infections. However, the quality control of CP and individual variation in patients in different studies make it rather difficult to evaluate the efficacy and risk of CP therapy for coronavirus disease 2019 (COVID-19). We aimed to explore the potential efficacy of CP therapy, and to assess the possible factors associated with its efficacy. We enrolled eight critical or severe COVID-19 patients from four centers. Each patient was transfused with 200–400 mL of CP from seven recovered donors. The primary indicators for clinical efficacy assessment were the changes of clinical symptoms, laboratory parameters, and radiological image after CP transfusion. CP donors had a wide range of antibody levels measured by serology tests which were to some degree correlated with the neutralizing antibody (NAb) level. No adverse events were observed during and after CP transfusion. Following CP transfusion, six out of eight patients showed improved oxygen support status; chest CT indicated varying degrees of absorption of pulmonary lesions in six patients within 8 days; the viral load was decreased to a negative level in five patients who had the previous viremia; other laboratory parameters also tended to improve, including increased lymphocyte counts, decreased C-reactive protein, procalcitonin, and indicators for liver function. The clinical efficacy might be associated with CP transfusion time, transfused dose, and the NAb levels of CP. This study indicated that CP might be a potential therapy for severe patients with COVID-19.

Signal Transduction and Targeted Therapy (2020)5:219 ; https://doi.org/10.1038/s41392-020-00329-x

INTRODUCTION

In December 2019, the outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, and has rapidly spread around the world.1 COVID-19 can manifest on a spectrum of illness from mild disease to severe respiratory failure requiring intensive care unit admission. The World Health Organization (WHO) has declared COVID-19 a pandemic on March 11, 2020. As of May 17, 2020, it had caused a total of 4,525,497 cases of infection and resulted in 307,395 deaths globally.2

Epidemiology and etiology for COVID-19 are rapidly evolving, giving us a greater understanding of those at risk and elucidating more potential therapy targets.3 In addition to supportive care, such as oxygen support and extracorporeal membrane oxygenation, several drugs for this disease are still being researched, such as remdesivir, lopinavir/ritonavir, arbidol, and darunavir.3,4 However, up to now, no approved vaccine or specific antiviral agents has been proved to be effective to prevent or treat SARS-CoV-2 infection due to the absence of evidence.

Passive immunity delivered as neutralizing antibodies (NAb) from convalescent plasma (CP) may offer an alternative therapeutic approach for COVID-19.5 CP therapy has been empirically used in other epidemics, including SARS, Middle East respiratory syndrome (MERS), and 2009 influenza A (H1N1).6–10 A meta-analysis of 32 reports on SARS coronavirus infection and severe influenza revealed a statistically significant reduction of mortality after administration of CP, especially when CP was given early after symptom onset.6 However, in a case series on influenza A (H5N1) virus infection, nonsignificant benefits following the intervention of CP were reported,11 and no association of CP therapy with an increased survival was observed in 84 patients with Ebola virus disease.12 It is possibly due to the unknown levels of NAb in the infused plasma, which may obscure the effects of CP.13 In this current pandemic, preliminary studies suggested the effectiveness of CP with no severe adverse events to treat patients infected with SARS-CoV-2.13–17 The results from a pilot study applying CP transfusion for 10 severe patients showed that administration of CP with NAb titers above 1:640 led to improvement in clinical symptoms and pulmonary lesions.14

1National Engineering Research Center of Immunological, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Third Military Medical University, Chongqing, P.R. China; 2State Key Laboratory of Trauma, Burn and Combined Injury, Third Military Medical University, Chongqing, P.R. China; 3Institute of Blood Transfusion, Chongqing Blood Center, Chongqing, P.R. China; 4Chongqing Public Health Medical Central, Chongqing, P.R. China; 5Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control, Beijing, P.R. China; 6Chongqing University Three Gorges Hospital & Chongqing Three Gorges Central Hospital, Chongqing, P.R. China; 7Affiliated Hospital of North Sichuan Medical College, Nanchong, P.R. China and 8Yongchuan Hospital of Chongqing Medical University, Chongqing, P.R. China

Correspondence: Wei Mao (maoweicpcb@163.com) or Yaokai Chen (yaokaichen@hotmail.com) or Quanming Zou (qmzou2007@163.com)

These authors contributed equally: Hao Zeng, Dongfang Wang, Jingmin Nie, Haoyu Liang, Jiang Gu

Received: 9 July 2020 Revised: 27 August 2020 Accepted: 14 September 2020
Published online: 06 October 2020
These findings indicate that CP transfusion may be a promising therapy in the treatment for COVID-19.

Nonetheless, due to the limitations of the study design and small sample size, current evidence on the efficacy and safety of CP therapy for COVID-19 is still limited. Moreover, the quality control of CP and individual variation in patients in different studies makes it rather difficult to evaluate the efficacy and risk of CP therapy. Thus, more supporting evidence (such as multi-level assessment of specific antibodies in CP, indications for CP treatment, and selection of transfusion timing) is called for with wider adoption of CP for COVID-19 in multi-centers and regions. Herein, we performed a retrospective observational study involving eight critical or severe patients with COVID-19 from four designated hospitals in the southwest region of China, aiming to explore the potential efficacy and safety of CP therapy, and to provide more evidence for the quality control of donated plasma and reasonable clinical application of CP transfusion.

RESULTS
Clinical characteristics of the patients
A total of 8 patients (4 males and 4 females) with critical or severe COVID-19 were enrolled. The median age was 65.0 years (IQR, 63.0–67.0 years). The median time from symptom onset to hospital admission was 4.0 days (interquartile interval (IQR), 3.0–8.5 days). The most common symptoms during hospitalization were cough (7/8), shortness of breath (5/8), and fever (4/8), while patients had fewer manifestations of dyspnoea (two cases), diarrhea (two cases), headache (one case), and fatigue (one case). Five patients had coexisting chronic diseases at admission, including type II diabetes, hypertension, chronic obstructive pulmonary disease (COPD), and coronary heart disease (CHD).

Table 1 listed the drug treatments prior to and after CP transfusion. All 8 patients received combination therapy of various antiviral treatment and other supportive care. The most commonly used antivirals were interferon alfa-1b (8/8), lopinavir/ritonavir (7/8), and arbidol (7/8). Darunavir and hydroxychloroquine sulfate were also administered for three and two patients, respectively. Antibiotic or antifungal agents were used when patients had co-infection. Five patients were given corticosteroids at the appropriate situation. Chest computed tomography (CT) scans demonstrated that all patients presented bilateral multiple ground-glass opacity or partial consolidation at the time of admission, with primary involvement of subpleural lesions.

Characteristics of convalescent plasma donors
In total, seven donors (5 males and 2 females) from the participating hospitals who had recovered from SARS-CoV-2 infection donated 300–400 mL of CP (Table 2). The median age was 37.0 years (IQR, 34.0–42.5 years). These donors donated the CP at the median day of 11.0 (IQR, 9.5–17.5 days) from discharge. All of 7 donors were mild or moderate patients during a hospital stay with no comorbidities.

We measured SARS-CoV-2 specific antibodies using four platforms of immunological tests. The SARS-CoV-2 specific antibody titers were detected by magnetic chemiluminescence enzyme immunoassays (MCLIA) which targeted at the combination of nucleoprotein (NP) and receptor binding domains of spike protein (S-RBD) specific antigens, as well as by enzyme-linked immunosorbent assays (ELISA) which determined anti-NP and anti-S-RBD specific IgG antibodies separately. The IgG titers detected by MCLIA ranged from 1:160 to 1:1280, and the IgM MCLIA titers were less than or equal to 1:50 in six donors, except donor 4 (1:320). The ELISA results showed that the anti-S-RBD and anti-NP specific IgG titers were in a range of 1:640–1:2560 and 1:320–1:5120, respectively. We measured the inhibitory activity of receptor binding (RBIA) of the CP samples by a receptor-binding assay, finding the 50% inhibitory titer (IT50) values ranging from 1:3 to 1:74. Importantly, the neutralizing activity of these plasma samples, which offer the most informative assessment of antiviral activity of patient sera against viral infection, was measured by a pseudovirus based neutralization assay. The Nabs of the donated plasma also showed variable levels (NAb titer (NAT50) range, 1:255–1:1576), and only three CP donors (donor 4, 5, and 7) had NAT50 values greater than 1:640.

The results of correlation analyses as shown in Fig. 1a indicated that there was positive correlation between IgG MCLIA titer and S-RBD specific IgG ELISA titer ($r = 0.94$, $P = 0.029$). NAT50 was positively correlated with S-RBD and NP specific IgG ELISA titers, respectively ($r = 0.87$, $P = 0.019$; $r = 0.93$, $P = 0.007$, respectively). However, the positive association between IgG MCLIA titer and NAT50 did not show statistical significance ($r = 0.77$, $P = 0.071$). Notably, IT50 was neither related to NAT50, nor correlated to IgG titers. Comparing the antibody levels of CP collected at different time, we found that the CP donated greater that 21 days had higher levels of S-RBD IgG ELISA titer and IgG MCLIA titer than CP which collected less than or equal to 21 days (Fig. 1b).

Clinical response of CP transfusion
Adverse Effects of CP Transfusions. No adverse events were observed in the eight patients after CP transfusion.

Clinical characteristics. As the patients have been treated by antiviral drugs and oxygen support before CP therapy, the body temperature, heat rate, and systolic pressure were normal even prior to CP transfusion, and kept unchanged within 5 days after CP transfusion as indicated in Table 4. Individual patient’s change in the category of oxygen support during hospitalization is shown in Fig. 2. Six of eight patients showed an improvement in the category of oxygen support within 5 days from CP treatment. Obvious improvement was observed in patients who were receiving high-flow nasal cannula oxygenation ($n = 3$), or non-invasive positive pressure ventilation (NIPPV, $n = 3$) prior to CP treatment. It is notable that patient 1, 2, and 5 rapidly shifted high-flow supplemental oxygen or NIPPV to low-flow supplemental oxygen within 24 h after CP transfusion.

Pulmonary lesions on chest CT examinations. Chest CT scans showed that pulmonary lesions improved at varying degrees in six out of eight patients. A partial resolution of pulmonary lesions was observed in patient 2, 3, and 4 on 1st day, in patient 6 and 7 on 3rd day, in patient 4 on 5th day, and in patient 1 on 8th day after plasma transfusion, respectively. Representative chest CT images of patient 1–3 were shown on Fig. 3.

Laboratory results. We monitored the development of the virus-specific IgG and IgM antibodies by MCLIA prior to and after CP transfusion in all patients except patient 5. In 5 of 7 patients, the IgG titer increased within 2 days posttransfusion, with patient 4, 7, and 8 presenting the most obvious increment (Fig. 4a). The IgM level was observed lower than IgG for all patients, and waved in a small range after CP transfusion (Fig. 4b).

SARS CoV-2 viral load, estimated by the cycle threshold (Ct) value from reverse transcriptase-polymerase chain reaction.
### Table 1. Basic clinical characteristics of patients with COVID-19

| Patients | Centers | Age | Sex | Smoking history | Estimated incubation period, days | Days from symptom onset to admission | Comorbidities | Principal symptoms during hospitalization | Treatments |
|----------|---------|-----|-----|-----------------|-----------------------------------|--------------------------------------|--------------|-----------------------------------------|------------|
| 1        | 1       | 70  | Female | None             | 4                                 | 7                                    | None         | Cough, sputum production, shortness of breath, diarrhea | Lopinavir/ritonavir, arbidol, interferon alf-1b* |
| 2        | 1       | 64  | Female | None             | None                              | 3                                    | None         | Cough, shortness of breath              | Lopinavir/ritonavir, arbidol, interferon alf-1b* |
| 3        | 1       | 46  | Female | None             | None                              | 10                                   | Hypertension | Cough, dyspnoea, shortness of breath    | Lopinavir/ritonavir, arbidol, interferon alf-1b* |
| 4        | 2       | 60  | Male   | None             | None                              | 10                                   | COPD         | Fever, cough, dyspnoea                 | Arbidol, interferon alf-1b* |
| 5        | 3       | 84  | Male   | None             | None                              | 6                                    | PD           | Fever, cough, shortness of breath      | Lopinavir/ritonavir, arbidol, interferon alf-1b* |
| 6        | 4       | 66  | Female | None             | None                              | 2                                    | None         | Fever, headache, shortness of breath   | Lopinavir/ritonavir, arbidol, interferon alf-1b* |
| 7        | 4       | 65  | Male   | None             | Current smoking                   | 3                                    | Type II diabetes, CHD, COPD           | Lopinavir/ritonavir, arbidol, interferon alf-1b* |
| 8        | 4       | 65  | Male   | None             | None                              | 2                                    | None         | Confusion, static tremor, cough, sputum production | Moxifloxacin, cefoperazone sodium and sulbactam sodium, moxifloxacin, meropenem, piperacillin-tazobactam, imipenem and clastatin sodium |

**Treatments**
- **Antivirals**
  - Lopinavir/ritonavir, arbidol, interferon alf-1b*
  - Lopinavir/ritonavir, arbidol, interferon alf-1b*
  - Lopinavir/ritonavir, arbidol, interferon alf-1b*
  - Lopinavir/ritonavir, arbidol, interferon alf-1b*
  - Lopinavir/ritonavir, arbidol, interferon alf-1b*
  - Lopinavir/ritonavir, arbidol, interferon alf-1b*

- **Antibiotics or antifungal agents**
  - Moxifloxacin
  - Piperacillin-tazobactam, caspofungin
  - Moxifloxacin, piperacillin-tazobactam
  - Moxifloxacin, cefoperazone sodium and sulbactam sodium, moxifloxacin, meropenem, piperacillin-tazobactam, imipenem and clastatin sodium

- **Corticosteroids**
  - None
  - Methylprednisolone
  - Methylprednisolone
  - Methylprednisolone
  - Methylprednisolone
  - Methylprednisolone

- **Others**
  - Thymosin*
  - Thymosin*
  - Thymosin*
  - Thymosin*
  - Thymosin*
  - Thymosin*

*COPD: chronic obstructive pulmonary disease, PD: parkinson’s disease, CHD: coronary heart disease
*Regarding the drugs administered after the CP transfusion within 5 days. Center 1–4 were Chongqing Public Health Medical Center, Affiliated Hospital of North Sichuan Medical College, Yongchuan hospital of Chongqing Medical University, and Chongqing Three Gorges Central Hospital, respectively.
Concerning the parameters indicative of liver function, the increment of the ratios of proinflammatory cytokines and anti-inflammatory cytokines (IL-6/IL-10, and IL-6/IL-4) in four patients showed various alterations in each patient after CP treatment respectively, as compared to the status before CP therapy. Other patients (Fig.4j), and for 5 of 6 patients (Supplementary Fig. S1a), proinflammatory cytokines such as interferon-γ (IFN-γ), IL-2, IL-10, and IL-17A showed various alterations in each patient after CP treatment (Supplementary Fig. S1b-e). We also observed tendencies of IL-17A, showed various alterations in each patient after CP treatment (Table 4). Concerning the parameters indicative of liver function, the alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBIL) tended to decrease after CP therapy, except for an increase of all these indicators in patient 4, and elevated ALT and AST in patient 8. The coagulation profile of patients was also monitored following CP treatment, indicating that 5 out of 6 patients kept the normal level of prothrombin time, while abnormally elevated D-dimer prior to plasma transfusion (median, 1.2; IQR, 0.5–4.0) still increased within 5 days after plasma treatment in 4 of 6 patients (Supplementary Fig S1f).

### Table 2. Characteristics of convalescent plasma donors

| Donors | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|---|
| Blood products coding | 399 | 400 | 397 | 933 | 395 | 703 | 701 |
| Centers | 1 | 1 | 1 | 2 | 1 | 3 | 3 |
| Sex | Male | Female | Male | Male | Female | Male | Male |
| Age | 26 | 49 | 39 | 41 | 47 | 34 | 43 |
| Donated plasma volume, mL | 400 | 400 | 400 | 300 | 400 | 400 | 400 |
| Blood type | A | A | A | A | B | A | B |
| Clinical classification | Mild | Moderate | Mild | Mild | Moderate | Moderate | Moderate |
| Comorbidities | None | None | None | None | None | None | None |
| Estimated incubation period, d | – | 20 | 3 | – | 3 | 9 | 6 |
| Days of plasma donation from symptom onset | 16 | 19 | 30 | 30 | 33 | 19 | 22 |
| Anti-SARS-CoV-2 specific IgM MCLIA titer | <1:50 | 1:50 | <1:50 | 1:320 | 1:120 | 1:50 | 1:50 |
| Anti-SARS-CoV-2 specific IgG MCLIA titer | 1:160 | 1:160 | 1:320 | 1:120 | 1:120 | 1:160 | 1:1280 |
| Anti-S-RBD specific IgG ELISA titer | 1:640 | 1:640 | 1:1280 | 1:2560 | 1:2560 | 1:1280 | 1:2560 |
| Anti-NP specific IgG ELISA titer | 1:640 | 1:320 | 1:1280 | 1:2560 | 1:2560 | 1:1280 | 1:5120 |
| IT50 | 1:6 | 1:3 | 1:74 | 1:33 | 1:12 | 1:17 | 1:20 |
| NAT50 | 1:320 | 1:255 | 1:312 | 1:1529 | 1:852 | 1:460 | 1:1576 |

MCLIA magnetic chemiluminescence enzyme immunoassay, ELISA enzyme-linked immunosorbent assay, S-RBD receptor binding domains of spike protein, NP nucleoprotein, IT50 inhibitory titer which was calculated with the dilution of plasma that inhibits 50% RBD-Fc binding to receptor ACE2, NAT50 neutralizing antibody titer which was calculated with the highest dilution of plasma that resulted in a 50% reduction of virus infection.

Center 1–3 were Chongqing Public Health Medical Center, Affiliated Hospital of North Sichuan Medical College, and Chongqing Three Gorges Central Hospital, respectively.
multiple organ dysfunction syndrome (MODS), and deep vein thrombosis in lower limb (LDVT).

**DISCUSSION**

This retrospective observational study explored the potential efficacy and safety of CP treatment in 8 patients who were critically or severely ill with COVID-19. One or two doses of CP with a total of 300–400 mL was well tolerated by all patients without any adverse effects. Improved clinical conditions as indicated by improvement of oxygen support and chest CT imaging were observed in most patients after CP treatment. The viral load as estimated by the Ct value also declined to undetectable level within 7 days post transfusion.

It has been suggested that CP served as a method of passive immunity therapy, which could significantly reduce the mortality of patients with SARS infection. One possible mechanism for the efficacy of CP therapy is the NAb from CP which may lead to the clearance of viraemia. Our results showed that only plasma from donor 4, 5, and 7 had relatively high neutralizing activity (NAT50 > 1:640). This is consistent with a recent finding that the majority of CP donors had relatively modest neutralizing activity and a small proportion of donors had high neutralization activity. It is not surprising since all donors were previously moderate or mild patients, and there is evidence that mild patients frequently had a lower level of SARS-CoV-2 specific antibodies than severe patients.

Assessing the effects of neutralizing activity of CP on the patients’ clinical efficacy, we found that patients treated by CP with high NAT50 (>1:640) had more obvious improvement than patients receiving low NAT50 value (≤1:640) of CP, including shorter negative conservation time of viral RNA, and higher increment of IgG level after CP transfusion. In line with other publications, our results indicated that CP with high concentration of NAb may contribute to the clearance of the virus. Based on the fact that CP donors who usually recovered from mild infection may not generate adequate protective antibodies, and the levels of plasma neutralizing activity required to prevent SARS-CoV-2 re-infection are currently unknown, more studies are necessary to assess the minimum threshold of NAb titers necessary to prevent SARS-CoV-2 re-infection.

In addition to pseudovirus based neutralization test, this study also employed multiple SARS-CoV-2 serology tests and receptor-binding assay. The results demonstrated that CP donors had a wide range of antibody levels measured across multiple platforms. Pseudotyped virus assay, an alternative of neutralization test which is considered as the optimal assay to determine the antiviral activity of antibodies, could measure how effectively donor plasma or serum can inhibit virus infection of target cells. But it is not feasible to implement neutralization test or pseudotyped virus assay as a measurement of antiviral antibodies for general population investigation. By contrast, serology tests are more convenient and practical. Here we examined the correlations between serology test results and neutralization assay in the CP samples, which is seldomly explored in other studies. Our results indicated that S-RBD and NP specific IgG ELISA titers had a significant strong correlation with NAT level, and IgG MCLIA titer showed a modest correlation with neutralization activity. However, the inhibitory activity of receptor binding of the CP samples had a low degree of association with neutralization activity. These findings may provide some clues about that ELISA or MCLIA assays may serve as a surrogate for pseudovirus neutralization assay to predict the degree of neutralization activity present in recovered patients or vaccine recipients. Studies with larger sample size are necessary to further explore these alternative serology tests which could help to refine the CP selection, as well as inform immunogenicity of vaccines against SARS-CoV-2.

The treatment timing is considered as another important factor associated with the effectiveness of CP therapy. Viraemia reaches to the peak in the first week of infection for most viral illnesses. Patients usually develops a primary immune response by days 10–14, which is followed by virus clearance. The largest study involved the CP treatment of 80 patients in Hong Kong with SARS found that the better clinical outcome was observed among patients who were given CP before day 14 of illness and among cases who were PCR positive and seronegative for coronavirus at the time of plasma infusion. A recent study on COVID-19 demonstrated that CP therapy could not reduce the mortality rate in critically ill patients with end-stage disease. Thus, to obtain the greatest benefit from CP, treatment should be...
| Patients | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|----------|---|---|---|---|---|---|---|---|
| Complications prior to CP treatment | Bacterial pneumonia | Hyperlipidaemia | None | Bacterial pneumonia, ARDS, MODS, LDVT | Fungal pneumonia, cardiac failure, anemia | None | Bacterial pneumonia | Fungal pneumonia, LDVT |
| Clinical classification prior to CP treatment | Severe | Critical | Severe | Critical | Severe | Severe | Severe | Severe |
| Days of CP transfusion from symptom onset | 30 | 12 | 17 | 23 | 34 | 26 | 9 | 28 |
| Total transfusion volume, mL | 400 | 400 | 400 | 300 | 400 | 200 | 200 | 200 |
| 1st transfusion | | | | | | | | |
| CP donor | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 6 |
| Time | Feb 18, 00:10 a.m. | Feb 18, 00:15 a.m. | Feb 29, 10:00 a.m. | Feb 20, 14:05 p.m. | Mar 5, 20:10 p.m. | Feb 23, 13:20 p.m. | Feb 23, 13:10 p.m. | Feb 23, 13:10 p.m. |
| Dose, mL | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 |
| 2nd transfusion | | | | | | | | |
| CP donor | 2 | 1 | 3 | 4 | 5 | – | – | – |
| Time | Feb 18, 12:30 p.m. | Feb 18, 12:30 p.m. | Mar 1, 10:05 a.m. | Feb 21, 15:05 p.m. | Mar 6, 8:45 a.m. | – | – | – |
| Dose, mL | 200 | 200 | 200 | 100 | 200 | – | – | – |
| Clinical outcome | Discharge | Discharge | Discharge | Remain hospitalized | Discharge | Discharge | Discharge | Discharge |
| Length of hospital stay, days | 36 | 20 | 18 | – | 35 | 28 | 28 | 30 |

*CP convalescent plasma, ARDS acute respiratory distress syndrome, MODS multiple organ dysfunction syndrome, LDVT deep vein thrombosis in lower limb*
Clinical features and laboratory results before and after convalescent plasma transfusion

| Clinical characteristics | Before CP transfusion | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 |
|--------------------------|-----------------------|-------|-------|-------|-------|-------|
| **Clinical characteristics** |                       |       |       |       |       |       |
| Body temperature, °C      | 36.5 (36.3–36.6)      | 36.6 (36.2–36.9) | 36.6 (36.3–36.9) | 36.6 (36.3–36.8) | 36.5 (36.3–36.8) | 36.4 (36.3–37.1) |
| Respiratory rate, per min | 19.5 (19.0–25.5)      | 21.0 (20.0–23.5) | 20.5 (20.0–21.0) | 21.5 (19.0–22.0) | 20.0 (19.3–21.8) | 20.0 (19.0–25.0) |
| Heart rate                | 77.5 (64.0–92.5)      | 81.0 (72.0–87.8) | 78.0 (62.5–88.0) | 84.5 (73.3–91.5) | 87.0 (79.8–89.8) | 100.0 (81.5–121.5) |
| Systolic pressure         | 118.0 (105.0–129.0)   | 112.5 (106.8–119.5) | 116.0 (114.5–128.0) | 116.5 (109.0–123.3) | 108.0 (106.0–116.0) | 118.0 (109.5–125.8) |
| PaO₂/FiO₂ (normal range, 400–500 mmHg) | 259.0 (163.0–283.0) | 312.0 (246.0–409.0) | 318.0 (279.5–416.0) | 225.0 (194.5–444.5) | 290.0 (196.0–493.5) | 326.0 (215.3–556.0) |
| **Laboratory results**    |                       |       |       |       |       |       |
| WBC count x 10⁹/L (normal range, 3.5–9.5) | 7.5 (5.5–8.4) | 8.3 (7.0–9.2) | 7.4 (5.5–7.9) | 6.6 (5.5–9.9) | 6.7 (5.8–10.9) | 7.9 (5.6–13.2) |
| NE count x 10⁹/L (normal range, 1.8–6.3) | 6.1 (4.4–7.3) | 6.9 (4.5–8.4) | 5.7 (4.7–6.9) | 5.0 (4.2–8.4) | 4.5 (3.5–9.0) | 6.0 (3.5–11.8) |
| LY count x 10⁹/L (normal range, 1.1–3.2) | 0.4 (0.2–1.5) | 0.7 (0.3–1.2) | 0.8 (0.2–1.2) | 0.8 (0.4–1.3) | 1.1 (0.5–1.5) | 1.1 (0.7–1.4) |
| CRP, mg/L (normal range, <8) | 10.9 (7.7–94.0) | 11.7 (8.1–51.4) | 41.7 (9.5–66.8) | 24.9 (6.3–107.4) | 24.1 (6.1–95.2) | 41.9 (5.0–58.1) |
| PCT, ng/mL (normal range, <0.1) | 0.15 (0.06–0.38) | 0.09 (0.05–0.18) | 0.05 (0.05–0.13) | 0.04 (0.03–0.12) | 0.04 (0.01–0.09) | 0.01 (0.01–0.11) |
| IL-2, pg/mL (normal range, 0–5.71) | 1.1 (0.6–1.6) | 0.9 (0.6–0.9) | 0.8 (0.6–3.6) | 1.3 (1.0–2.1) | 0.5 (0.4–1.3) | 1.0 (0.5–2.7) |
| IL-4, pg/mL (normal range, 0–2.80) | 1.6 (0.7–2.1) | 0.5 (0.3–2.4) | 1.4 (0.7–3.3) | 1.5 (0.4–2.2) | 0.4 (0.2–1.1) | 0.7 (0.6–5.1) |
| IL-6, pg/mL (normal range, 0–5.30) | 7.8 (1.8–26.8) | 10.5 (1.1–12.8) | 12.7 (5.1–32.8) | 11.6 (4.3–68.0) | 23.6 (4.3–58.3) | 6.6 (5.5–35.6) |
| IL-10, pg/mL (normal range, 0–491) | 3.1 (2.6–3.7) | 3.3 (2.3–10.9) | 3.6 (2.5–6.9) | 3.6 (3.5–3.7) | 3.5 (2.7–3.9) | 3.8 (3.3–4.1) |
| IL-17A, pg/mL (normal range, 0–20.60) | 8.2 (0.7–17.0) | 1.5 (0.7–83) | 1.5 (0.0–24.5) | 14.0 (3.4–26.7) | 8.2 (0.0–12.7) | 12.3 (1.5–52.0) |
| TNF-α, pg/mL (normal range, 0–2.31) | 3.3 (0.6–3.7) | 1.5 (1.3–5.5) | 3.2 (1.2–5.8) | 2.4 (1.2–4.6) | 1.2 (0.9–2.1) | 2.3 (1.4–5.8) |
| IFN-γ, pg/mL (normal range, 0–7.42) | 1.4 (1.3–2.8) | 2.7 (1.0–4.7) | 1.5 (1.1–3.7) | 2.3 (1.3–3.6) | 1.3 (1.0–2.4) | 2.2 (0.6–4.4) |
| IL-6/IL-10               | 1.4 (0.6–4.0) | 0.7 (0.3–1.4) | 4.2 (2.0–13.3) | 2.3 (1.2–10.1) | NA | 1.7 (1.5–4.2) |
| IL-6/IL-4                | 4.5 (2.0–4.7) | 12.4 (5.6–19.7) | 9.6 (3.7–46.9) | 19.3 (4.3–50.3) | NA | 9.5 (6.9–20.9) |
| ALT, μL (normal range, 5–40) | 21.1 (14.3–47.0) | 22.0 (17.0–49.5) | 22.0 (14.5–49.1) | 23.0 (18.0–51.7) | 20.4 (15.8–40.2) | 27.8 (14.0–65.0) |
| AST, μL (normal range, 13–35) | 20.2 (16.3–30.8) | 19.0 (16.4–25.0) | 18.0 (15.5–30.3) | 18.0 (16.0–32.3) | 17.0 (15.3–24.0) | 18.4 (14.0–33.6) |
| TBIL, μmol/L (normal range, 0–26) | 17.5 (7.1–24.7) | 10.4 (6.6–15.4) | 10.4 (5.8–15.8) | 12.0 (9.2–14.2) | 10.4 (6.3–16.6) | 10.8 (9.6–24.6) |
| PT, second (normal range, 11–14) | 11.3 (10.6–12.4) | 11.3 (10.1–13.3) | 10.6 (9.5–12.9) | 10.4 (9.6–13.9) | 10.5 (9.6–13.4) | 10.9 (10.1–12.9) |
| D-dimer, mg/mL (normal range, 0–0.05) | 1.2 (0.5–4.0) | 1.0 (0.4–5.7) | 0.9 (0.6–5.3) | 0.8 (0.6–5.4) | 1.1 (0.6–4.2) | 1.2 (0.8–3.3) |

Data are indicated as median (IQR)

*CP* convalescent plasma, *WBC* white blood cell, *NE* neutrophil, *LY* lymphocyte, *CRP* C-reactive protein, *PCT* Procalcitonin, *IL* interleukin, *TNF* tumor necrosis factor, *IFN* interferon, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *PT* prothrombin time, *NA* not applicable
Chongqing Medical University, and Affiliated Hospital of North Sichuan Medical University. A total of 220 patients were originally enrolled in this study, 180 of whom were included in the final analysis. The remaining 40 patients were excluded due to incomplete data. All patients were confirmed to have COVID-19 by real-time reverse transcription polymerase chain reaction (RT-PCR) assays. The patients were divided into two groups: the CP therapy group and the control group. The CP therapy group received CP transfusion at an early stage (within 21 days from illness onset), while the control group did not receive any intervention. The study was performed from February 17, 2020, to April 10, 2020, at four centers, Chongqing Public Health Medical Center, Chongqing Three Gorges Central Hospital, Yongchuan Hospital of Chongqing Medical University, and Affiliated Hospital of North Sichuan Medical University. This study was performed from February 17, 2020, to April 10, 2020, at four centers, Chongqing Public Health Medical Center, Chongqing Three Gorges Central Hospital, Yongchuan Hospital of Chongqing Medical University, and Affiliated Hospital of North Sichuan Medical University.

The efficacy assessment of convalescent plasma therapy for COVID-19... Zeng et al.

Fig. 2 Changes in oxygen-support status from admission in individual patients. For each patient, the colors in the line represent the oxygen-support status of the patient over time. Invasive ventilation includes invasive mechanical ventilation. Noninvasive ventilation includes noninvasive positive pressure ventilation (NIPPV), high-flow oxygen therapy with nasal or face mask, and low-flow oxygen therapy with nasal. The vertical black arrows show the day of CP transfusion. The presentation of oxygen support status referred to a recent report.

Based on our findings, the dose of infused CP might play a role on its therapeutic effect, as demonstrated by the result that the viral nucleic acid in patients transfused with 400 mL of CP tended to turn faster to undetectable than that in patients who received 200 mL of CP. While a study about the CP therapy in SARS patients found that there was no correlation between clinical outcome and the volume of infused plasma. Future large-scale studies are needed to investigate the association between the dose of CP transfusion and its clinical efficacy.

There are some limitations that should be noted in this study. First, this study was a case series with small sample size, and the outcome of the CP treated patients was not compared with a control group of patients who did not receive the intervention. Second, the patients received other therapies (including antiviral agents, antibiotics or antifungal drugs, and corticosteroids), making it impossible to discriminate the specific contribution of CP to the clinical course or outcomes. Moreover, CP was administered 9–34 days after admission in this study. The association between the transfusion timing and clinical outcomes should be further clarified. In addition, patients in the current study were given different doses of CP. It is unclear whether the doses and the titers of antibodies were associated with the treatment efficacy. Despite these limitations, this study provided more evidence to support that CP therapy might be a promising option to treat COVID-19 patients, which is also supported by the recent issue by FDA of emergency use authorization for CP as potential promising COVID-19 treatment. Overall, this study not only provided more evidence on the potential efficacy and safety of CP therapy, but also contributed to the quality control of donated plasma and reasonable clinical application of CP transfusion.

In conclusion, our preliminary study indicated that CP might be a potential therapy for severe patients with COVID-19. We observed improvement of clinical features without the occurrence of serious adverse reactions following CP transfusion. Further well-designed randomized clinical trials are needed to evaluate the efficacy and safety of CP transfusion, and to explore best donation candidates with high virus-specific antibodies, and indications for CP therapy (e.g., optimal transfusion time point, early warning indicators, and transfused dose).

MATERIALS AND METHODS

Patients
This study was performed from February 17, 2020, to April 10, 2020, at four centers, Chongqing Public Health Medical Center, Chongqing Three Gorges Central Hospital, Yongchuan Hospital of Chongqing Medical University, and Affiliated Hospital of North Sichuan Medical University.
The efficacy assessment of convalescent plasma therapy for COVID-19…
Zeng et al.

Sichuan Medical College. All patients were diagnosed as critical or severe COVID-19 pneumonia according to the WHO Interim Guidance32 and the Guideline of Diagnosis and Treatment of COVID-19 of National Health Commission of China (version 6.0)33 with laboratory confirmation by real-time RT-PCR assay. Patients were enrolled to receive CP treatment if they met any of the following criteria: (1) respiratory distress (RR ≥ 30 breaths/min); (2) oxygen saturation at rest ≥93%; (3) PaO2/FIO2 ≥ 300 mmHg; (4) severe complications (e.g., respiratory failure, mechanical ventilation support, septic shock, or failure of other organs). Patients with any of the following conditions were excluded: (1) allergic history to plasma, plasma protein or sodium citrate; (2) other serious syndromes not suitable for CP transfusion, such as irreversible severe organ dysfunction. A total of 8 patients were treated with CP transfusion in the study.

This study was approved by the ethical committee of Chongqing Public Health Medical Center (approval number, 2020-030-01-KY). All patients signed a written informed consent before any procedure was carried out. If patients cannot make rational decisions, the consents were signed by their family members on behalf of the patients. This study was conducted in accordance with the Helsinki Declaration as revised 1981.

Donors for convalescent plasma transfusion
CP was obtained from donors who had recovered from COVID-19 infection. The recovery status was defined as follows: (1) aged between 18 and 55 years; (2) at least 3 weeks following symptom onset; (3) afebrile status for at least 3 days; (4) significant improvement in respiratory symptoms; (4) two consecutively negative results of sputum SARS-CoV-2 of real-time RT-PCR assay (one-day sampling interval). Persons who met all criteria were eligible for plasma donation. Written informed consent was obtained from each donor.

Plasma preparation
Apheresis was performed using Haemonetics MCS + LN90 00-220E blood cell separator (Haemonetics, Boston, MA, USA). Convalescence plasma for treatment was collected from 7 donors. A 200 or 400 mL of ABO-compatible plasma sample was collected from each donor, and each sample was divided and stored as 100 or 200 mL aliquots at 4°C without any detergent or heat treatment. The CP was then treated with methylene blue and light treatment for 30 min in the medical plasma virus inactivation cabinet (Shanghai blood technology Co., Ltd, Shanghai, China). The plasma samples were tested negative for hepatitis B virus, hepatitis C virus, HIV, syphilis, and blood type irregular antibody. As a routine check with plasma donation, the CP was also confirmed negative for residual SARS-CoV-2 by RT-PCR.

RT-PCR detection of SARS-CoV-2 RNA
Throat swab samples were collected from patients for extracting SARS-CoV-2 RNA using the RNA Viral Kit (Daan, Guangdong, China). The real-time RT-PCR assay was performed using commercials kit specific for SARS-CoV-2 nucleic acid detection (Liferiver, Shanghai, China; Shengxiang,Sansure Biotech, Hunan, China) approved by the China National Medical Products Administration (approve numbers, 20203400057 for Liferiver, and 20203400064 for Shengxiang). Two target genes, including open reading frame1ab (ORF1ab) and nucleocapsid protein (N), were simultaneously amplified using the real-time RT-PCR assay. Each transcript provided a Ct value, which is the number of cycles required for the fluorescent signal. A higher Ct value is correlated with a lower viral load. A Ct value less than 40 was defined as a positive result, and a Ct value of 40 or more was defined as a negative test. All procedures involving clinical specimens and SARS-CoV-2 were performed in a biosafety level 3 laboratory.

Detection of specific IgG and IgM levels against SARS-CoV-2
The collected CP and serum samples from the donors and patients were inactivated at 56 °C for 30 min and stored at −20 °C before testing, and serially diluted before determination. IgG and IgM against SARS-CoV-2 were tested using MCLIA kits supplied by Bioscience Co. (Tianjing, China) approved by the China National Medical Products Administration; approval numbers, 20203400183 (IgG) and 20203400182 (IgM), according to the manufacturer’s instructions. MCLIA for IgG or IgM detection was developed based on a double-antibody sandwich immunosassay. The recombinant antigens containing the nucleoprotein and a peptide from the spike protein of SARS-CoV-2 were conjugated with FITC and immobilized on anti-FITC antibody-conjugated magnetic particles.

Fig. 3 Chest CT scans of three patients. a Chest CT of patient 1 obtained on February 16 before CP transfusion (February 18) showed ground-glass opacity with uneven density, close to the pleura. b CT Image of patients 1 taken on February 26 showed partial absorption of bilateral ground-glass opacity. c Chest CT of patient 2 obtained on February 14 before CP transfusion (February 18) showed diffuse ground-glass opacity in both lungs. d CT Image of patients 2 taken on February 21 showed those lesions improved after CP transfusion. e CT Image of patients 3 taken on February 24 showed diffusion of bilateral ground-glass opacity before CP transfusion (February 29). f CT Image of patients 3 taken on March 4 showed those lesions improved after CP transfusion.
The tests were conducted on an automated magnetic chemiluminescence analyzer (Axceed 260, Bioscience, Tianjing, China) according to the manufacturer’s instructions. The MCLIA titers of specific IgG and IgM antibodies were defined as the highest dilution giving a chemiluminescence value of more than or equal to 1. All tests were performed under strict biosafety conditions. Detection of specific IgG levels against SARS-CoV-2 S-RBD and NP SARS-CoV-2 NP and S-RBD specific IgG antibodies in plasma were measured by in-house ELISA separately. Purified NP and S-RBD antigens were coated onto MaxiSorp ELISA plates (Corning Costar, Acton, MA, USA) in 0.1 M carbonate buffer (pH 9.6) at concentration of 0.2 μg/mL overnight at 4 °C, respectively. Plates were washed 4
times with phosphate-buffered saline (PBS) containing 0.1% vol/vol Tween-20 (PBST) and blocked with 1% bovine serum albumin for 2 h at 37 °C. The plates were then washed with PBST. The serum samples were diluted to 80-fold into PBS as initial concentration, and then serial 2-fold diluted until 81920-fold. The serial dilutions of serum samples were added to the plate wells and incubated, followed by wash and incubation with anti-human IgG HRP-conjugated coat secondary antibody (Abcam, Cambridge, UK). After 4 washes, plates were developed by tetrarmethylenzidine substrate (TianGen Biotech Co., Beijing, China) at room temperature in the dark. The absorbance was measured at 450 nm. All samples were run in duplicate. The absorbance was measured at 450 nm. All samples were run in duplicate. The titers of NP and S-RBD specific IgG antibodies were defined as the highest dilution giving an absorbance value of more than 2.1 times that of the negative control.

Receptor-binding assay
Inhibitory effects of the CP samples on RBD-Fc binding to receptor angiotensin-converting enzyme 2 (ACE2) were tested using an ELISA-based assay. Recombinant soluble human ACE2 (Sino Biological) was coated at 2 μg/ml to 96-well ELISA plates (Corning Costar) in 0.1 M carbonate buffer (pH 9.6) at 4 °C overnight. Plates were washed 4 times with 0.1% vol/vol PBST and blocked with 0.1% bovine serum albumin for 2 h at 37 °C. 80 ng/ml recombinant SARS-CoV-2 Spike RBD-mFc (Sino Biological) was mixed with the presence or absence of serially diluted CP or serum samples 1:1 and incubated at 37 °C for 1 h, then add the 100 μl mixed solution to the wells. Incubated at 37 °C for 10 min, 100 μl of the HRP conjugated goat anti-mouse IgG (ZSGB-BIO) was added to the wells. After incubation at 37 °C for 1 h, 100 μl of the substrate TMB was added to the wells. Developed at room temperature in the dark for 5 min, it was terminated with the stop solution (2 M sulphuric acid). The absorbance was measured at 450 nm. All samples were run in duplicate. The 50% inhibitory titer (IT50) was defined as the dilution of serum or plasma that inhibits 50% RBD-Fc binding to receptor ACE2 using a linear interpolation algorithm.

Pseudovirus based neutralization assay
The neutralization of plasma samples was measured by a pseudovirus-based neutralizing assay as described previously. In brief, pseudovirus was incubated with serial dilutions of the plasma samples (six dilutions in a 3-fold step-wise manner) in duplicate for 1 h at 37 °C, together with the virus control and cell control wells in triplicate. Then, freshly HuH-7 cells (Japanese Collection of Research Bioresources [JCRB], 9403) were added to each well. Following 24 h of incubation in a 5% CO2 environment at 37 °C, the luminescence was measured using a microplate luminometer (PerkinElmer, Ensign). The NAb titers (NAT50) were defined as the 50% inhibitory dilution (ID50) which was calculated with the highest dilution of plasma that resulted in a 50% reduction of virus infection.

Clinical data collection and efficacy assessment
Clinical information of the patients before and after CP transfusion was retrieved from the hospital electronic medical records system, including: (1) basic clinical data: age, sex, days of admission from symptom onset, presenting symptoms, comorbidities, and other treatments; (2) CP transfusion information: time and dose of CP infusion, complications prior to CP therapy, and adverse effects; (3) clinical features, laboratory data, and chest CT imaging.

Adverse events and serious adverse events associated with CP transfusion were assessed by the clinician. The primary indicators for efficacy assessment were the changes of clinical symptoms, laboratory parameters, and radiological image after CP intervention. Clinical outcomes include discharge and hospitalization.

Continuous variables were summarized as median and IQR or range. Spearman correlation analyses were used to calculate the correlations among log2-transformed anti-SARS-CoV-2 specific IgG and IgM MCLIA titers, anti-S-RBD and anti-NP specific IgG ELISA titers, IT50, and NAT50 of CP. Graphs were plotted using GraphPad Prism 7.0 (GraphPad Software, San Diego, CA, USA). Correlation analysis was performed using SPSS 22.0 (SPSS Inc., Chicago, IL, USA). Two-tailed P value of less than 0.05 was considered statistically significant.

DATA AVAILABILITY
The authors declare that the data supporting the findings of this study are available within the paper and its Supplementary materials.

ACKNOWLEDGEMENTS
This work was supported by the Emergency Project from the Science & Technology Commission of Chongqing (cstc2020jccx-fyxx0078) and Health Committee of Chongqing (2020NPZX11). We thank all patients and donors involved in this study.
REFERENCES
1. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
2. WHO. Novel coronavirus (COVID-19) situation. https://who.sprinklr.com (2020).
3. Dong, L., Hu, S. & Gao, J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Ther. 14, 58–60 (2020).
4. Barlow, A. et al. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy. https://doi.org/10.1002/phar.2398 (2020).
5. Grein, J. et al. Compassionate use of remdesivir for patients with severe Covid-19. N. Engl. J. Med. https://doi.org/10.1056/NEJNooa2007016 (2020).
6. Chen, L., Xiong, J., Bao, L. & Shi, Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis. 20, 398–400 (2020).
7. Cheng, Y. et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. 24, 44–46 (2005).
8. Mair-Jenkins, J. et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J. Infect. Dis. 211, 80–90 (2015).
9. Hung, I. F. et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis. 52, 447–456 (2011).
10. Ko, J. H. et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir. Ther. 23, 617–622 (2018).
11. Yu, H. et al. Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. PLoS ONE 3, e2985 (2008).
12. van Griensven, J. et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N. Engl. J. Med. 374, 33–42 (2016).
13. Shen, C. et al. Treatment of 5 critically Ill patients With COVID-19 with convalescent plasma. JAMA. https://doi.org/10.1001/jama.2020.4783 (2020).
14. Duan, K. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl Acad. Sci. USA. https://doi.org/10.1073/pnas.2004168117 (2020).
15. Zhang, B. et al. Treatment with convalescent plasma for critically Ill patients with SARS-CoV-2 infection. Chest. https://doi.org/10.1016/j.chest.2020.03.039 (2020).
16. Ye, M. et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J. Med. Virol. https://doi.org/10.1002/jmv.25882 (2020).
17. Ahn, J. Y. et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J. Korean Med. Sci. 35, e149 (2020).
18. WHO. Clinical management of severe acute respiratory infection when COVID-19 is suspected: interim guidance. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected (2020).
19. China NHCoC. Guideline for diagnosis and treatment for novel coronavirus pneumonia (sixth edition). http://www.nhc.gov.cn/xcs/zhenchengwj/202002/ 8334a8326dd94d329df3517da8ae6cf2.shtml (2020).
20. Nie, J. et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg. Microbes Infect. 9, 680–686 (2020).
21. Luke, T. C., Kilbane, E. M., Jackson, J. L. & Hoffman, S. L. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future HSNI treatment? Ann. Intern. Med. 145, 599–609 (2006).
22. Rajendran, K. et al. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J. Med. Virol. https://doi.org/10.1002/jmv.25961 (2020).
23. Bloch, E. M. et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J. Clin. Invest. https://doi.org/10.1172/JCI138745 (2020).
24. Shen, C. et al. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Sci. Transl. Med 9, eaam5752 (2017).
25. Luchsinger, L. L. et al. Serological analysis of New York City COVID19 convalescent plasma donors. medRxiv. Preprint at https://doi.org/10.1101/2020.06.08.20124792 (2020).
26. Cao, X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 20, 269–270 (2020).
27. Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa344 (2020).
28. Zeng, Q. L. et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J. Infect. Dis. 222, 38–43 (2020).
29. Moore, J. B. & June, C. H. Cytokine release syndrome in severe COVID-19. Science 368, 473–474 (2020).
30. Hirano, T. & Murakami, M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity 52, 731–733 (2020).
31. FDA. FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment. Another achievement in administration’s fight against pandemic, https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment.
32. Zhang, C., Wu, Z., Li, J. W., Zhao, H. & Wang, G. Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents 55, 105594 (2020).
33. Tan, L. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct. Target Ther. 5, 33 (2020).
34. Tiberghien, P. et al. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang. https://doi.org/10.1111/vox.12926 (2020).